Nationwide Fund Advisors’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-154,763
Closed -$8.66M 102
2017
Q3
$8.66M Buy
154,763
+15,541
+11% +$822K 0.03% 737
2017
Q2
$8.74M Buy
139,222
+11,268
+9% +$656K 0.04% 715
2017
Q1
$6.54M Sell
127,954
-6,621
-5% -$316K 0.03% 870
2016
Q4
$5.74M Buy
134,575
+13,511
+11% +$575K 0.02% 921
2016
Q3
$5.74M Sell
121,064
-2,900
-2% -$145K 0.02% 900
2016
Q2
$6.26M Buy
123,964
+105,671
+578% +$5.33M 0.03% 839
2016
Q1
$1.27M Sell
18,293
-213
-1% -$8.22K 0.01% 1578
2015
Q4
$728K Buy
18,506
+210
+1% +$8.4K ﹤0.01% 1894
2015
Q3
$695K Sell
18,296
-2,649
-13% -$112K ﹤0.01% 1913
2015
Q2
$832K Sell
20,945
-9,406
-31% -$293K ﹤0.01% 1963
2015
Q1
$813K Sell
30,351
-714
-2% -$20.1K ﹤0.01% 1990
2014
Q4
$912K Sell
31,065
-265
-0.8% -$6.54K ﹤0.01% 1855
2014
Q3
$632K Sell
31,330
-217
-0.7% -$4.19K ﹤0.01% 2069
2014
Q2
$528K Buy
+31,547
New +$447K ﹤0.01% 2230
2014
Q1
Sell
-34,615
Closed -$506K 3092
2013
Q4
$506K Sell
34,615
-771
-2% -$12.4K ﹤0.01% 2239
2013
Q3
$609K Buy
35,386
+4,868
+16% +$72.2K ﹤0.01% 2118
2013
Q2
$355K Buy
+30,518
New +$350K ﹤0.01% 2197

Other funds holding AMED

Nationwide Fund Advisors's AMED Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Amedisys (AMED) in Q4 2017, closing a stake of 154,763 shares — an estimated $8.66M sold.

Nationwide Fund Advisors first reported a position in AMED in Q2 2013 and held it in 17 quarters. The position peaked at $8.74M in Q2 2017. 188 funds tracked by Wall St. Rank hold AMED as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Amedisys position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 154,763 Amedisys shares in Q4 2017, an estimated $8.66M.
  • Nationwide Fund Advisors first reported a position in Amedisys in Q2 2013 and held it in 17 quarters.
  • Nationwide Fund Advisors's Amedisys position peaked at $8.74M in Q2 2017.
  • 188 funds tracked by Wall St. Rank held Amedisys as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.